1. Home
  2. AMCX vs DBVT Comparison

AMCX vs DBVT Comparison

Compare AMCX & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMCX
  • DBVT
  • Stock Information
  • Founded
  • AMCX 1980
  • DBVT 2002
  • Country
  • AMCX United States
  • DBVT France
  • Employees
  • AMCX N/A
  • DBVT N/A
  • Industry
  • AMCX Cable & Other Pay Television Services
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AMCX Telecommunications
  • DBVT Health Care
  • Exchange
  • AMCX Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • AMCX 312.4M
  • DBVT 260.5M
  • IPO Year
  • AMCX 2011
  • DBVT N/A
  • Fundamental
  • Price
  • AMCX $8.20
  • DBVT $9.84
  • Analyst Decision
  • AMCX Sell
  • DBVT Buy
  • Analyst Count
  • AMCX 5
  • DBVT 4
  • Target Price
  • AMCX $6.50
  • DBVT $14.81
  • AVG Volume (30 Days)
  • AMCX 408.7K
  • DBVT 33.0K
  • Earning Date
  • AMCX 11-07-2025
  • DBVT 11-05-2025
  • Dividend Yield
  • AMCX N/A
  • DBVT N/A
  • EPS Growth
  • AMCX N/A
  • DBVT N/A
  • EPS
  • AMCX N/A
  • DBVT N/A
  • Revenue
  • AMCX $2,354,176,000.00
  • DBVT $3,800,000.00
  • Revenue This Year
  • AMCX N/A
  • DBVT $1,743.46
  • Revenue Next Year
  • AMCX N/A
  • DBVT $1,045.66
  • P/E Ratio
  • AMCX N/A
  • DBVT N/A
  • Revenue Growth
  • AMCX N/A
  • DBVT N/A
  • 52 Week Low
  • AMCX $5.41
  • DBVT $2.21
  • 52 Week High
  • AMCX $10.60
  • DBVT $12.78
  • Technical
  • Relative Strength Index (RSI)
  • AMCX 54.19
  • DBVT 54.64
  • Support Level
  • AMCX N/A
  • DBVT $9.58
  • Resistance Level
  • AMCX $8.48
  • DBVT $10.50
  • Average True Range (ATR)
  • AMCX 0.27
  • DBVT 0.52
  • MACD
  • AMCX -0.23
  • DBVT 0.07
  • Stochastic Oscillator
  • AMCX 96.70
  • DBVT 63.33

About AMCX AMC Networks Inc.

AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: